Sentinel node biopsy in breast cancer and melanoma requires adequate self-audit

ANZ Journal of Surgery

Volumn 74, Issue 5, 2004, Pages 308-313

  Spillane, Andrew ^a,b,c,d,e  

^a SYDNEY CANCER CENTRE   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c Mater Hospital   (Australia)

^d St Lukes Hospital   (Australia)

^e PRINCE OF WALES PRIVATE HOSPITAL   (Australia)

Author keywords

Audit; Breast cancer; Melanoma; Sentinel node biopsy

Indexed keywords

AXILLA; BREAST CANCER; CANCER STAGING; DATA ANALYSIS; DATA BASE; DISSECTION; FEMALE; FOLLOW UP; HUMAN; MELANOMA; OUTCOMES RESEARCH; REVIEW; SELF EVALUATION; SENTINEL LYMPH NODE BIOPSY; STATISTICAL PARAMETERS; SURGICAL TECHNIQUE; VALIDATION PROCESS;

AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; MEDICAL AUDIT; MELANOMA; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 2542594644     PISSN: 14451433     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-1433.2004.02987.x     Document Type: Review

References (60)

1. Balch CM, Buzaid AC, Soong S et al. The final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J. Clin. Oncol. 2001; 19: 3635-48.
2. Martin RCG, Fey J, Yeung H, Borgen PI, Cody HS. High isotope count does not predict sentinel node positivity in all breast cancer patients. Ann. Surg. Oncol. 2001; 8: 592-7.
3. Veronesi U, Paganelli G, Galimberti V et al. Sentinel node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997; 349: 1864-7.
4. Guiliano AE. Current status of sentinel lymphadenectomy in breast cancer. Ann. Surg. Oncol. 2001 ; 8: 52S-55S.
5. Mignotte H, Treilleux I, Faure C, Nessah K, Bremond A. Axillary lymph-node dissection for positive sentinel nodes in breast cancer patients. Eur. J. Surg. Oncol. 2002; 28: 623-6.
6. Gill G (Study Chair). Sentinel Lymph Node Biopsy Versus Axillary Clearance in Operable Breast Cancer. The RACS SNAC Trial, Version 1.0. Camperdown: NHMRC Clinical Trials Centre.
7. Kollias J, Gill PG, Chatterton BE et al. Reliability of sentinel node status in predicting axillary lymph node involvement in breast cancer. Med. J. Aust. 1999; 171: 461-5.
8. Molland JG, Dias MM, Gillett DJ. Sentinel node biopsy in breast cancer: results in 103 cases. Aust. N. Z. J. Surg. 2000; 70: 98-102.
9. Mann BG, Buchanan M, Collins PJ, Lichtenstein M. High incidence of micrometastases in breast cancer sentinel nodes. Aust. N. Z. J. Surg. 2000; 70: 786-90.
10. ALMANAC. A randomised trial of sentinel node guided axillary therapy compared to standard axillary therapy in early breast cancer. London: Protocol MRC, 1999.
11. National Surgical Adjuvant Breast and Bowel Project (NSABP). Protocol B-32. A randomized, Phase III Clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. Pittsburgh: NSABP Operations Centre. [cited 24 March 2004]. Available from: http://www.nsabp.pitt.edu
12. American College of Surgeons Oncology Group. Z0010 A prognostic study of sentinel node and bone marrow micrometastases in women with clinical T1 or T2, N0M0 breast cancer. Amendment #7, Revision #1. [cited 24 March 2004]. Available from: http://www.acosog.org
13. American College of Surgeons Oncology Group. Z0011 A randomized trial of axillary node dissection in women with clinical T1 or T2, N0M0 breast cancer who have a positive sentinel node. Amendment #6, Revision #1. [cited 24 March 2004]. Available from: http://www.acosog.org
14. AMAROS (After Mapping of the Axilla: Radiotherapy or Surgery). EORTC Breast Cancer Cooperative Group Protocol 10981 - Summary. 1999.
15. Cox CE, Pendas S, Cox JM et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann. Surg. 1998; 227: 645-51.
16. Schwartz GF, Giuliano AE, Veronesi U, the Consensus Conference Committee. Proceedings of the Consensus Conference on the Role of Sentinel Lymph Node Biopsy in Carcinoma of the Breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer 2002; 94: 2542-51.
17. Morton DL (principal investigator). 'A Clinical Study of Wide excision alone versus wide excision with intraoperative lymphatic mapping and selective lymph node dissection in treatment of patients with cutaneous invasive melanoma.' Available from: http://www.skincancer.org/melanoma/lymphadenectamy. php
18. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977; 39: 456-66.
19. Morton D, Wen D, Cochran A. Management of early-stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy: an alternative to routine elective lymphadenectomy or 'watch and wait'. Surg. Oncol. Clin. N. Am. 1992; 1: 247-59.
20. Guiliano AE, Dale PS, Roderick R, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann. Surg. 1995; 222: 394-401.
21. Krag DN, Weaver DL, Alex JC et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using gamma probe. Surg. Oncol. 1993; 2: 335-40.
22. Bilchik AJ, Saha S, Tsioulias GJ, Wood TF, Morton DL. Aberrant drainage and missed micrometastases, the value of lymphatic mapping and focused analysis of sentinel lymph nodes in gastrointestinal neoplasms. Ann. Surg. Oncol. 2001; 8: 82S-85S.
23. Aikou T, Higashi H, Natsugoe S, Hokita S, Baba M, Tako S. Can sentinel node navigation surgery reduce the extent of lymph node dissection in gastric cancer? Ann. Surg. Oncol. 2001; 8; 90S-93S.
24. Paramo JC, Summerall J, Poppiti R, Mesko TW. Validation of sentinel node mapping in patients with colon cancer. Ann. Surg. Oncol. 2002; 9: 550-4.
25. Coit DG. Merkel cell carcinoma. Ann. Surg. Oncol. 2001; 8 (Suppl): 99S-102S.
26. Mozzillo N, Chiesa F, Botti G et al. Sentinel node biopsy head neck cancer. Ann. Surg. Oncol. 2001; 8 (Suppl): 103S-105S.
27. Sener SF, Winchester DJ, Martz CH et al. Lymphedema after sentinel lymphadenectomy for breast cancer. Cancer 2001; 92: 748-52.
28. Haid A, Kuehn T, Konstantiniuk P et al. Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer. Eur. J. Surg. Oncol. 2002; 28: 705-10.
29. Mcmasters KM, Giuliano AE, Ross MI et al. Sentinel-lymphnode biopsy for breast cancer - not yet the standard of care. N. Engl. J. Med. 1998; 339: 990-5.
30. Shivers S, Cox C, Leight G et al. Final results of the Department of Defense multicenter breast lymphatic mapping trial. Ann. Surg. Oncol. 2002; 9: 248-55.
31. Krag D, Weaver D, Ashikaga T et al. The sentinel node in breast cancer - a multicenter validation study. N. Engl. J. Med. 1998; 339: 941-6.
32. Balch CM, Soong S-J, Bartolucci AA et al. Efficacy of an elective regional lymph node dissection of 1-4 mm thick melanomas for patients 60 years of age and younger. Ann. Surg. 1996; 224: 255-63.
33. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin. Proc. 1986; 61: 697-705.
34. Gershenwald JE, Colome MI, Lee JE et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. Clin. Oncol. 1998; 16: 2253-60.
35. Roumen RMH, Kuijt GP, Leim IH, van Beck MW. Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissection. Br. J. Surg. 2001; 88: 1639-43.
36. Zurrida S. Early results of sentinel node biopsy randomized trial in T1N0 breast cancer. Ann. Surg. Oncol. 2002; 9: S29
37. Chung MA, Steinhoff MM, Cady B. Clinical axillary recurrence in breast cancer patients after a negative sentinel node biopsy. Am. J. Surg. 2002; 184: 310-14.
38. Roumen RMH, Kuijt GP, Liem IH, van Beck MWPM. Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissection. Br. J. Surg. 2001; 88: 1639-43.
39. Jakub JW, Pendas S, Reintgen DS. Current status of sentinel lymph node mapping and biopsy: Facts and Controversies. Oncologist 2003; 8: 59-68.
40. Fisher B, Redmond C, Fisher E et al. Ten year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N. Engl. J. Med. 1985; 312: 674-81.
41. Forrest APM, Everington D, Mcdonald CC, Steele RJC, Chetty U, Stewart HJ. The Edinburgh randomized trial of axillary sampling or clearance after mastectomy. Br. J. Surg. 1995; 82: 1504-8.
42. Sledge GW (ed). Highlights of the 2000 NIH Consensus Conference on Adjuvant Therapy for Breast Cancer. [cited 24 March 2004]. Available from: consensus.nih.gov
43. Sosa JA, Diener West M, Gusev Y et al. Association between extent of axillary lymph node dissection and survival in patients with stage 1 breast cancer. Ann. Surg. Oncol. 1998; 5: 140-9.
44. Overgaard M, Hansen PS, Overgaard J et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvnat chemothreapy: Danish Breast Cancer Cooperative Group 82b Trial. N. Engl. J. Med. 1997; 337: 949-55.
45. Overgaard M, Jensen MB, Overgaard J et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641-8.
46. Ragaz J, Jackson SM, Le NPI et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N. Engl. J. Med. 1997; 337: 956-62.
47. Uren RF, Howman-Giles RB, Thompson JF et al. Mammary lymphoscintigraphy in breast cancer. J. Nucl. Med. 1995; 36: 1775-80.
48. Bevilacqua JL, Gucciardo G, Cody Iii HS et al. A selection algorithm for internal mammary sentinel lymph node biopsy in breast cancer. Eur. J. Surg. Oncol. 2002; 28: 603-14.
49. Sacks NP, Baum M. Primary management of carcinoma of the breast. Lancet 1993; 342: 1402-8.
50. Veronesi U, Cascinelli N, Greco M et al. Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann. Surg. 1985; 202: 702-7.
51. Mcmasters KM, Wong SL, nd RC et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel node biopsy: results of a multiinstitutional study. Ann. Surg. 2001; 233: 676-87.
52. Kern KA. Lymphoscintigraphic anatomy of sentinel lymphatic channels after subareolar injection of Technetium 99m sulphur colloid. J. Am. Coll. Surg. 2001; 193: 601-8.
53. Borgstein PJ, Meijer S, Pijpers RJ, van Diest PJ. Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue dye method. Ann. Surg. 2000; 232: 81-9.
54. Quan ML, Mccready D, Temple WJ, Mckinnon JG. Biology of lymphatic metastases in breast cancer: lessons learned from sentinel node biopsy. Ann. Surg. Oncol. 2002; 9: 467-71.
55. Martin RCII, Edwards MJ, Wong SL et al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For University Louisville Breast Cancer Study Group. Surgery 2000; 128: 139-44.
56. Thompson JF. The Sydney Melanoma Unit experience of sentinel lymphadenectomy for melanoma. Ann. Surg. Oncol. 2002; 8 (suppl): 44S-47S.
57. Doting MH, Hoekstra HJ, Plukker J et al. Is sentinel node biopsy beneficial in melanoma patients? A report on 200 patients with cutaneous melanoma. Eur. J. Surg. Oncol. 2002; 28: 673-8.
58. Mcmasters KM, Wong SL, Edwards MJ et al. Frequency non-sentinel lymph node metastasis melanoma. Ann. Surg. Oncol. 2002; 9: 137-41.
59. Dessureault S, Soong S-J, Ross MI et al. Improving staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann. Surg. Oncol. 2001; 8: 766-70.
60. Statius Muller MG, van Leeuwen PA, de Lange-De Klerk ES et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with stage I or II cutaneous melanoma. Cancer 2001; 15: 2401-8.